Key Takeaways Novartis to acquire Excellergy for up to $2B, adding Exl-111 to expand its IgE-focused pipeline.NVS strengthens allergy franchise with next-gen anti-IgE therapy targeting food allergy and asthma.Deal aligns with immunology push as Novartis advances pipeline amid patent and generic pressures.Novartis (NVS) has announced the proposed acquisition of Excellergy Inc., reinforcing its strategic focus on expanding its immunology pipeline, particularly in food allergy and other IgE-mediated diseases.E ...

Core Insights - Novartis received FDA approval for a label expansion of its psoriasis drug Cosentyx, now indicated for pediatric patients aged 12 and older with moderate to severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor available for this demographic [1][7] - Cosentyx generated sales of $6.7 billion in 2025, reflecting an 8% increase from 2024, driven by demand from recent launches and growth in core indications [5][7] - The approval for pediatric use is supported by adult HS studies and pharmacokinetic modeling, indicating comparable drug exposure between pediatric and adult patients [3][4] Product and Market Performance - Cosentyx is already approved for multiple conditions, including HS, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, marking its fourth pediatric indication [4][7] - The drug's sales growth is attributed to continued demand from recent launches, including the HS indication and an intravenous formulation in the U.S. [5][7] - However, Cosentyx is set to lose exclusivity in the U.S. in 2029, which may impact future sales [8] Strategic Developments - Novartis is focusing on key growth drivers such as Kisqali, Kesimpta, Pluvicto, and Scemblix to support overall revenue growth [10] - The company recently acquired Avidity Biosciences, enhancing its neuromuscular pipeline and potentially unlocking multi-billion-dollar market opportunities with product launches targeted before 2030 [11][12] - Novartis projects a net sales compound annual growth rate (CAGR) of 5-6% at constant currency from 2025 to 2030, bolstered by advancements in its late-stage pipeline [12]

Core Insights - The government has negotiated prices for 10 popular prescription drugs under Medicare Part D for 2026, which will significantly reduce costs for seniors on fixed incomes [1][5]. Group 1: Negotiated Drugs and Pricing - The negotiated prices for a 30-day supply of the drugs include: - Januvia at $113.00 with a 79% discount - Fiasp and related products at $119.00 with a 76% discount - Farxiga at $178.50 with a 68% discount - Enbrel at $2,355.00 with a 67% discount - Jardiance at $197.00 with a 66% discount - Stelara at $4,695.00 with a 66% discount - Xarelto at $197.00 with a 62% discount - Eliquis at $231.00 with a 56% discount - Entresto at $295.00 with a 53% discount - Imbruvica at $9,319.00 with a 38% discount [3][4]. Group 2: Financial Implications - There is a $2,100 out-of-pocket maximum for all Part D beneficiaries, ensuring that seniors will not pay more than this amount for their prescription medications [4]. - Seniors should consider these negotiated prices when planning their healthcare budgets for 2026, as prices may increase slightly in future years due to inflation [5].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [2] Core Insights - 2025 saw a record high in innovative drug asset transactions among multinational pharmaceutical companies, with 142 cases and a total transaction value of $264.5 billion, marking new highs since 2015 [3][9] - Eli Lilly's revenue for 2025 increased by 44% year-on-year, driven by GLP-1 drugs, with Tirzepatide achieving $36.5 billion in sales [3][39] - Novo Nordisk's sales growth was impacted by increased competition in the weight loss drug market, with a projected revenue decline of 5% to 13% for 2026 [3][40] Summary by Sections 1. Innovative Drug Asset Transactions - In 2025, the number of innovative drug transactions reached 142, with mergers and acquisitions (M&A) and collaborations at 36 and 106 respectively, both setting new records since 2015 [3][9] - The total transaction value was $264.5 billion, with M&A accounting for $106 billion and collaborations for $158.4 billion, also new highs since 2015 [3][9] 2. Performance Review of Pharmaceutical Companies - Eli Lilly's total revenue for 2025 was $65.2 billion, with a guidance for 2026 revenue between $80 billion and $83 billion, indicating a projected growth of 25% [3][39] - Novo Nordisk's total revenue for 2025 was 309.1 billion Danish Kroner, with a guidance for 2026 indicating a decline of 5% to 13% [3][40] - Other companies like AbbVie, AstraZeneca, and Roche reported single-digit growth, while JNJ and Gilead faced challenges due to patent expirations [3] 3. Factors Influencing M&A Decisions - Demand for acquisitions is driven by the need to address revenue gaps from expiring patents and declining R&D efficiency [3][19] - Financial capacity for M&A is supported by free cash flow after shareholder returns, allowing for smaller acquisitions [3][20] - Pricing considerations are crucial, as the valuation of innovative drug assets significantly impacts the internal rate of return (IRR) for acquisitions [3][21]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [2] Core Insights - 2025 saw a record high in innovative drug asset transactions among multinational pharmaceutical companies, with 142 cases and a total transaction value of $264.5 billion, marking new highs since 2015 [3][9] - Eli Lilly's revenue for 2025 increased by 44% year-on-year, driven by GLP-1 drugs, with Tirzepatide achieving $36.5 billion in sales [3][39] - Novo Nordisk's sales growth was impacted by increased competition in the weight loss drug market, with a projected revenue decline of 5% to 13% for 2026 [3][40] Summary by Sections 1. Innovative Drug Asset Transactions - In 2025, the number of innovative drug transactions reached 142, with mergers and acquisitions (M&A) and collaborations at 36 and 106 respectively, both setting new records since 2015 [3][9] - The total transaction value was $264.5 billion, with M&A accounting for $106 billion and collaborations for $158.4 billion, also new highs since 2015 [3][9] 2. Performance Review of Pharmaceutical Companies - Eli Lilly's total revenue for 2025 was $65.2 billion, with a guidance of $80 billion to $83 billion for 2026, indicating a projected growth of 25% [3][39] - Novo Nordisk's revenue for 2025 was 309.1 billion Danish Krone, with a guidance for 2026 indicating a decline of 5% to 13% [3][40] - Other companies like AbbVie, AstraZeneca, and Roche reported single-digit growth, while JNJ and Gilead faced challenges due to patent expirations [3] 3. Factors Influencing M&A Decisions - Demand for acquisitions is driven by the need to address revenue gaps from expiring patents and declining R&D efficiency [3][19] - Financial capacity for M&A is supported by free cash flow after shareholder returns, allowing for smaller acquisitions [3][20] - Pricing considerations are crucial, as the valuation of innovative drug assets significantly impacts the internal rate of return (IRR) for acquisitions [3][21]

Industry Overview - The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a few pharma and biotech companies left to report [1] - As of February 11, 73.3% of companies in the Medical sector, representing 91% of the sector's market capitalization, reported quarterly earnings, with 86.4% exceeding both earnings and sales estimates [2][10] - Overall, fourth-quarter earnings in the medical sector are expected to decrease by 0.6%, while sales are projected to rise by 10.4% compared to the previous year [4] Company Performance Johnson & Johnson - Reported strong fourth-quarter results, beating estimates for both earnings and sales [3] Novartis - Beat earnings estimates but faced revenue pressure due to generic competition for key drugs like Entresto and Promacta [3] Bristol Myers Squibb - Beat both earnings and sales estimates and issued encouraging guidance [3] Gilead Sciences - Earnings exceeded both top and bottom lines, supported by higher sales of HIV and Liver Diseases drugs [3] Bausch Health - Mixed performance with two earnings beats and two misses in the last four quarters, delivering a four-quarter average negative surprise of 6.26% [5] - Scheduled to report on February 18, with an Earnings ESP of -8.84% and a Zacks Rank 3 [7] Amicus Therapeutics - Disappointing earnings track record with three misses and one beat in the last four quarters, averaging a negative surprise of 20.21% [8] - Set to be acquired by BioMarin, with its lead drug Galafold showing solid uptake [9] BioMarin Pharmaceutical - Impressive track record, beating earnings estimates in each of the last four quarters with an average surprise of 66.51% [11] - Scheduled to report with an Earnings ESP of -3.23% and a Zacks Rank 3, driven by strong demand for its dwarfism drug Voxzogo [12] Insmed - Poor earnings track record with four consecutive misses, averaging a negative surprise of 20.64% [13] - Scheduled to report on February 19, with an Earnings ESP of +7.01% and a Zacks Rank 3 [14] - Lead drug Arikayce gaining traction, with a new drug approval marking a significant milestone [15] Madrigal Pharmaceuticals - Missed earnings expectations in three of the last four quarters, with an average negative surprise of 17.17% [16] - Scheduled to report on February 19, with an Earnings ESP of -852.37% and a Zacks Rank 4 [16][17]

Core Viewpoint - Novartis' innovative pipeline significantly supports its performance, but short-term challenges may hinder the stock price from breaking historical highs [1] Performance Overview - Novartis continues to advance innovation through its "4+5" strategy, focusing on four major therapeutic areas and five technology platforms [2] - In 2025, several innovative drugs showed strong performance: - Oncology: CDK4/6 inhibitor Kisqali sales increased by 57%, radioligand therapy Pluvicto generated $1.994 billion in revenue (up 42%), and leukemia drug Scemblix grew by 85% [2] - Neuroscience: Multiple sclerosis drug Kesimpta sales rose by 36%, contributing to a 25% revenue growth in this segment [2] - Research and development progress includes the approval of 13 new products and indications in China in 2025, achieving 100% synchronization with global new drug development [2] - Pluvicto received approval in China for prostate cancer, and the production base in Haiyan, Zhejiang, is expected to be operational by the end of 2026, enhancing supply capacity [2] Recent Company Status - Despite the significant potential of its innovative pipeline, several factors may restrict short-term stock performance: - Patent cliff pressure: Core product Entresto faced a 45% year-on-year sales decline in Q4 2025 due to generic competition, with an estimated $4 billion in sales expected to be affected by patent expirations in the coming years [3] - Policy and market environment: The U.S. market experienced an 11% year-on-year sales decline in Q4 due to the impact of the Inflation Reduction Act, with ongoing litigation regarding this act contributing to policy uncertainty that may suppress valuations [3] - Financial data volatility: Free cash flow in Q4 2025 was $1.247 billion, a significant decline of 59.27% year-on-year, indicating short-term cash flow pressure [3] Capital Movements - Novartis reinforced confidence through active capital allocation, with total stock buybacks reaching $8.9 billion in 2025 and a proposed increase in the dividend to 3.70 Swiss francs per share (up 5.7% year-on-year) [4] - The total free cash flow for the year was $17.686 billion, providing support for future R&D and acquisitions [4] Recent Stock Performance - As of February 13, 2026, Novartis' stock price closed at $163.02, with a single-day increase of 1.14% and a year-to-date increase of 18.24% [5] - The price-to-earnings ratio (TTM) stands at 22.80, indicating a reasonable valuation range [5] - Overall, Novartis' innovative pipeline in oncology and neuroscience demonstrates technological leadership and resilient performance growth, but short-term patent expirations and policy uncertainties may limit the momentum for the stock to break historical highs [5]

Core Insights - Novartis (NVS) announced positive results from the late-stage III ALIGN study for its kidney disease drug Vanrafia (atrasentan) [1][9] - The ALIGN study demonstrated that Vanrafia effectively slows the decline of kidney function in patients with IgA nephropathy [3][4] Study Results - Vanrafia showed a significant difference in estimated glomerular filtration rate (eGFR) change from baseline compared to placebo, with a 2.39 ml/min/1.73m² difference at week 136 and a 2.59 ml/min/1.73m² difference at week 132 [3][4] - The study included a subgroup of patients receiving SGLT2 inhibitors, who also exhibited similar benefits [4] Regulatory Status - Vanrafia received accelerated approval in the United States and China in 2025 for reducing proteinuria in adults with IgA nephropathy, with plans for traditional approval in 2026 [5][9] Product Portfolio - Novartis' renal portfolio includes Fabhalta (iptacopan), which is approved for treating adults with paroxysmal nocturnal hemoglobinuria and has also received accelerated approval for IgA nephropathy [6] - Fabhalta generated sales of $155 million in Q4 and $505 million in 2025 [7] Market Context - 2026 is a critical year for Novartis due to the patent expiry of its cardiovascular drug Entresto, which is the largest in its history [8] - Novartis shares have increased by 52.9% over the past year, outperforming the industry growth of 20.6% [8]

Core Viewpoint - Novartis demonstrates strong revenue growth driven by innovative drugs, despite facing short-term challenges from market policies and patent expirations [1][3]. Financial Performance - In 2025, Novartis achieved a total revenue of $54.811 billion, reflecting a year-on-year growth of 8.99% [1]. - Key growth drivers include innovative drugs such as Kisqali (44% growth at constant exchange rates), Pluvicto (70% growth), and Scemblix (87% growth) [1]. - The fourth quarter saw significant contributions from these products, offsetting declines in sales from mature products like Entresto, which experienced a 45% year-on-year drop in sales [1]. Product Development Progress - Novartis is advancing its innovation through a "4+5" strategy, focusing on four therapeutic areas and five technology platforms [2]. - In 2025, the company received approval for 13 new products and indications in China, achieving 100% synchronization with global new drug development [2]. - Recent key developments include the approval of Pluvicto for prostate cancer in China, with a production base in Zhejiang expected to be operational by the end of 2026 [2]. - Positive data from late-stage pipelines, including gene therapy OAV101IT and small RNA drug Leqvio, are anticipated, with over 15 key data readouts expected in the next two years [2]. Industry Policy and Environment - Despite the potential of its innovative pipeline, the company faces short-term challenges, including an 11% year-on-year decline in sales in the U.S. market due to the Inflation Reduction Act [3]. - The expiration of the patent for core product Entresto is expected to intensify competition from generics, putting pressure on sales in 2026 [3]. - The current price-to-earnings ratio (TTM) stands at 22.54, indicating a reasonable valuation, but there are concerns regarding the potential impact of policy implementation on profits [3]. Capital Movements - In 2025, the company enhanced shareholder returns through stock buybacks totaling $8.9 billion and a 5.7% year-on-year increase in dividends [4]. - Free cash flow reached $17.686 billion, providing support for research and development as well as acquisitions [4]. - Overall, Novartis's innovative pipeline in oncology and cardiovascular fields shows technological leadership and resilient growth, although short-term patent expirations and policy uncertainties may limit the stock's ability to break historical highs [4].

Core Insights - Novartis reported high single-digit sales growth for 2025, achieving a 40.1% core margin two years ahead of schedule, with full-year sales rising 8% and core operating income increasing 14% to CHF 21.9 billion [3][4][6] Financial Performance - In Q4, sales declined by 1%, while core operating income rose by 1%. Excluding R&D-related adjustments, underlying Q4 sales growth would have been approximately 3% [2][6] - For the full year, core EPS increased by 17% to $8.98, and free cash flow grew by 8% to CHF 17.6 billion, marking an all-time high for the company [3][6] Product and Pipeline Momentum - Priority brands such as Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix, and Cosentyx showed strong growth, with Kisqali sales rising 57% to CHF 4.8 billion and Kesimpta sales increasing 36% to $4.4 billion [5][7][15] - Pluvicto achieved $2 billion in global sales with a 42% constant-currency growth, while Leqvio reached blockbuster status with 57% full-year growth [7][15] Pipeline Updates - Novartis highlighted several pipeline developments, including a submission for remibrutinib and updates on the renal portfolio, with a revised timeline for the zigakibart phase III protocol expected in the first half of 2027 [8][9] - Data from the Phase III MANIFEST program for pelabresib provided a path forward for registration, with plans for a new Phase III study targeting patients with high baseline symptom burden [10] 2026 Outlook - The company anticipates low single-digit sales growth for 2026, with a core margin decline of one to two percentage points due to the Avidity deal, describing the year as "a year of two halves" [12][14] - The first half of 2026 is expected to see low single-digit sales decline and low double-digit core operating income decline, while the second half is projected to grow mid-single-digit in sales and mid- to high single-digit in core operating income [14] Capital Allocation - In 2025, Novartis invested over $10 billion in R&D, completed a CHF 15 billion buyback program, and proposed a dividend of CHF 3.70 per share, marking the 29th consecutive dividend increase [16]